Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report

Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report

Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial growth factors have provided the basis for improved outcomes in select patients with unresectable or metastatic hepatocellular carcinoma. However, for patients with resectable disease, surgery alone or an orthotopi...

Full description

Bibliographic Details
Main Authors:	Maen Abdelrahim, Abdullah Esmail, Godsfavour Umoru, Kiersten Westhart, Ala Abudayyeh, Ashish Saharia, Rafik M. Ghobrial
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Series:	Current Oncology
Subjects:	transplant oncology liver transplantation hepatocellular carcinoma immunotherapy immune checkpoint inhibitors CTLA-4 inhibitors
Online Access:	https://www.mdpi.com/1718-7729/29/6/341

Similar Items

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
by: Maen Abdelrahim, et al.
Published: (2022-06-01)

Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?
by: Alexander Ciurej, et al.
Published: (2023-12-01)

Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation
by: Xinjun Lu, et al.
Published: (2024-11-01)

Focal Update on Immunotherapy and Liver Transplantation in the Era of Transplant Oncology
by: Maen Abdelrahim, et al.
Published: (2024-08-01)

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
by: Noha Abdel-Wahab, et al.
Published: (2019-04-01)

Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
by: Elizabeth M. Burton, et al.
Published: (2022-06-01)

Current advances in immunotherapy for cancer
by: Indrajit Desai, et al.
Published: (2024-12-01)

Role of gut microbiome on immunotherapy efficacy in melanoma
by: Stefano Bibbò, et al.
Published: (2022-05-01)

Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
by: Maen Abdelrahim, et al.
Published: (2022-05-01)

PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database
by: Alexandre O. Gérard, et al.
Published: (2025-01-01)

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
by: Jingyu Jiang, et al.
Published: (2023-02-01)

Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
by: Shun Kawashima, et al.
Published: (2022-06-01)

Immunotherapies in rare cancers
by: Sneha Vivekanandhan, et al.
Published: (2023-02-01)

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma
by: Li-ming Zhao, et al.
Published: (2023-03-01)

Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits
by: Mónica Bolufer, et al.
Published: (2024-11-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

The association between pretransplant malignancy and post-transplant survival and cancer recurrence in bilateral lung transplantation: An analysis of 23,291 recipients
by: Wongi Woo, MD, et al.
Published: (2025-02-01)

Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art
by: Laschtowitz A, et al.
Published: (2023-02-01)

Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response
by: Tristan Rupp, et al.
Published: (2022-06-01)

Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer
by: Hongsheng Zhang, et al.
Published: (2023-10-01)

“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management
by: Pietro Sollena, et al.
Published: (2022-05-01)

Immunotherapy in genitourinary malignancies
by: Kathan Mehta, et al.
Published: (2017-04-01)

A Novel CTLA-4 affinity peptide for cancer immunotherapy by increasing the integrin αvβ3 targeting
by: Ying Zhou, et al.
Published: (2022-10-01)

Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer
by: Osamu Kanai, et al.
Published: (2021-03-01)

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
by: Dia Roy, et al.
Published: (2023-10-01)

Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease
by: Emily Allen, et al.
Published: (2023-10-01)

Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers
by: Ashton A. Connor, et al.
Published: (2022-11-01)

Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
by: Connor Frey, et al.
Published: (2024-07-01)

Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors
by: LI Tao, et al.
Published: (2023-05-01)

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy
by: Julie N. Graff, et al.
Published: (2020-08-01)

Ketosis versus carbotoxicity – metabolism determines the outcome of cancer immunotherapy
by: Aitziber Buqué, et al.
Published: (2021-01-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
by: Adel Naimi, et al.
Published: (2022-04-01)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
by: Jianmin Wu, et al.
Published: (2021-06-01)

Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
by: Ludovico Abenavoli, et al.
Published: (2023-08-01)

Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review
by: Yu CW, et al.
Published: (2020-11-01)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
by: Jun Kamei, et al.
Published: (2022-05-01)

Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation
by: Federico Simonetta, et al.
Published: (2019-05-01)

Relationships among microbiota, gastric cancer, and immunotherapy
by: Yuzhen Li, et al.
Published: (2022-09-01)

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
by: Pottayil G. Sasikumar, et al.
Published: (2020-12-01)

A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety
by: Nestor Rubio-Infante, et al.
Published: (2022-03-01)